This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bragg, L.E. Articles by Thompson, J.S. Search for Related Content PubMed PubMed Citation Articles by Bragg, L.E. Articles by Thompson, J.S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITROGEN Social Bookmarking                         What's this?

Urogastrone Reduces Gut Atroprhy during Parenteral Alimentation

Departments of Surgery, University of Nebraska, Omaha Veterans Administration and Creighton Universily Medical Centers. Omaha, Nebraska

T.C. Hollingsed, M.D.

Departments of Surgery, University of Nebraska, Omaha Veterans Administration and Creighton Universily Medical Centers. Omaha, Nebraska

J.S. Thompson, M.D.

Departments of Surgery, University of Nebraska, Omaha Veterans Administration and Creighton Universily Medical Centers. Omaha, Nebraska

Urogastrone (UG) exerts trophic effects on the intestine and may play a role in maintaining normal intestinal structure and function. Since administration of nutrients parenterally results in intestinal hypoplasia and hypofunction, the aim of this study was to determine the effects of UG on intestinal structure and function in parenterally fed rats. Central venous catheters were placed into 28 Sprague-Dawley rats. Group I (n = 10) received TPN alone. Group II (n = 8) received TPN and 15 µg/day of UG and group III (n = 10) received rat chow ad libitum. The animals that received urogastrone had significantly greater (p < 0.05) intestinal weight (25.6 ± 2.5 mg/cm us 22.6 ± 3.0 mg/cm), mucosal weight (8.4 + 1.4 mg/cm us 6.2 ± 0.9 mg/cm), mucosal protein content (6.2 ±1.7 mg/ cm us 2.7 ± 0.6 mg/cm), villous height (427 ± 27 µm us 293 ± 75 µm), crypt cell production rate (14.5 ± 1.4 metaphases/hr us 12.3 ± 0.7 metaphases/hr) and sucrase specific activity (6.5 ± 2.6 us 3.7 ± 2.0) than animals receiving only TPN. However, these parameters remained less than in chow-fed animals. Thus, simultaneous infusion of UG prevents, in part, intestinal hypofunction and hypoplasia which occurs during TPN. This may be due to maintenance of mucosal proliferative activity and brush border enzyme activity. (Journal of Parenteral and Enteral Nutrition 14:283-286, 1990)

Journal of Parenteral and Enteral Nutrition, Vol. 14, No. 3, 283-286 (1990)
DOI: 10.1177/0148607190014003283


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W.-M. Wong and N. A. Wright Epidermal Growth Factor, Epidermal Growth Factor Receptors, Intestinal Growth, and Adaptation JPEN J Parenter Enteral Nutr, September 1, 1999; 23(5_suppl): S83 - S88. [Abstract] [PDF]

				J. S. Thompson Epidermal Growth Factor and the Short Bowel Syndrome JPEN J Parenter Enteral Nutr, September 1, 1999; 23(5_suppl): S113 - S116. [Abstract] [PDF]

				Y. Inoue, J. P. Grant, and P. J. Snyder Effect of Glutamine-Supplemented Total Parenteral Nutrition on Recovery of the Small Intestine After Starvation Atrophy JPEN J Parenter Enteral Nutr, March 1, 1993; 17(2): 165 - 170. [Abstract] [PDF]

				W. S. Helton and R. Garcia Oral Prostaglandin E2 Prevents Gut Atrophy During Intravenous Feeding but Not Bacterial Translocation Arch Surg, February 1, 1993; 128(2): 178 - 184. [Abstract] [PDF]